Who
Eric A. Hughes
See "Remarks"
Company insider
Files Form 4 as: See "Remarks", Teva Pharmaceutical Industries; Director, Monte Rosa Therapeutics.
In numbers
- Trades disclosed
- 63
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $11.7M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Aug 2022
- Last trade
- 3 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 5 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —52,744 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $892K25,578 at $34.88 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —52,744 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —52,744 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —52,744 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $892K25,578 at $34.88 | filing |
| 11 Jun 2026filed 12 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —19,654 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $302K9,533 at $31.67 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —19,654 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —19,654 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —19,654 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $302K9,533 at $31.67 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —23,251 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $366K11,277 at $32.46 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,251 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,251 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,643 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,643 at $0.00 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 16 Oct 2026Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $50.00TEVA · dailypolitical.com · 15 Oct 2026Analyzing Astrazeneca (NYSE:AZN) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Eric A. Hughes; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.